Cannabidiol potentiates pharmacological effects of Δ9-tetrahydrocannabinol via CB1 receptor-dependent mechanism

被引:101
作者
Hayakawa, Kazuhide [1 ]
Mishima, Kenichi [1 ]
Hazekawa, Mai [1 ]
Sano, Kazunori [1 ]
Irie, Keiichi [1 ]
Orito, Kensuke [3 ]
Egawa, Takashi [1 ]
Kitamura, Yoshihisa [1 ]
Uchida, Naoki [4 ]
Nishimura, Ryoji [4 ]
Egashira, Nobuaki [1 ]
Iwasaki, Katsunori [1 ,2 ]
Fujiwara, Michihiro [1 ,2 ]
机构
[1] Fukuoka Univ, Fac Pharmaceut Sci, Dept Neuropharmacol, Fukuoka 8140180, Japan
[2] Fukuoka Univ, Adv Mat Inst, Fukuoka 8140180, Japan
[3] Azabu Univ, Sch Vet Med, Dept Vet Pharmacol, Sagamihara, Kanagawa 2298501, Japan
[4] Fukuoka Univ, Dept Psychiat, Fukuoka 8140180, Japan
关键词
Delta(9)-tetrahydrocannabinol; cannabidiol; CB1; receptor; central nervous system; marijuana;
D O I
10.1016/j.brainres.2007.09.090
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Cannabidiol, a non-psycho active component of cannabis, has been reported to have interactions with Delta(9)-tetrahydrocannabinol (Delta(9)-THC). However, such interactions have not sufficiently been clear and may have important implications for understanding the pharmacological effects of marijuana. in the present study, we investigated whether cannabidiol modulates the pharmacological effects of Delta(9)-THC on locomotor activity, catalepsy-like immobilisation, rectal temperature and spatial memory in the eight-arm radial maze task in mice. in addition, we measured expression level of cannabinoid CB1 receptor at striatum, cortex, hippocampus and hypothalamus. Delta(9)-THC (1, 3, 6 and 10 mg/kg) induced hypoactivity, catalepsy-like immobilisation and hypothermia in a dose-dependent manner. In addition, Delta(9)-THC (1, 3 and 6 mg/kg) dose-dependently impaired spatial memory in eight-arm radial maze. On the other hand, cannabidiol (1, 3, 10, 25 and 50 mg/kg) did not affect locomotor activity, catalepsy-like immobilisation, rectal temperature and spatial memory on its own. However, higher dose of cannabidiol (10 or 50 mg/kg) exacerbated pharmacological effects of lower dose of Delta(9)-THC, such as hypoactivity, hypothermia and impairment of spatial memory. Moreover, cannabidiol (50 mg/kg) with Delta(9)-THC (1 mg/kg) enhanced the expression level of CB1 receptor expression in hippocampus and hypothalamus. Cannabidiol potentiated pharmacological effects of Delta(9)-THC via CB1 receptor-dependent mechanism. These findings may contribute in setting the basis for interaction of cannabinoids and to find a cannabinoid mechanism in central nervous system. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:157 / 164
页数:8
相关论文
共 47 条
[1]   Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential [J].
Ashton, CH ;
Moore, PB ;
Gallagher, P ;
Young, AH .
JOURNAL OF PSYCHOPHARMACOLOGY, 2005, 19 (03) :293-300
[2]   In silico patent searching reveals a new cannabinoid receptor [J].
Baker, D ;
Pryce, G ;
Davies, WL ;
Hiley, CR .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2006, 27 (01) :1-4
[3]   Evidence for novel cannabinoid receptors [J].
Begg, M ;
Pacher, P ;
Bátkai, S ;
Osei-Hyiaman, D ;
Offertáler, L ;
Mo, FM ;
Liu, H ;
Kunos, G .
PHARMACOLOGY & THERAPEUTICS, 2005, 106 (02) :133-145
[4]  
BISOGNO T, 2001, BRIT J PHARMACOL, V134, P825
[5]  
BORGEN LA, 1974, RES COMMUN CHEM PATH, V7, P663
[6]  
BORNHEIM LM, 1995, DRUG METAB DISPOS, V23, P825
[7]   Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression [J].
Carrier, Erica J. ;
Auchampach, John A. ;
Hillard, Cecilia J. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (20) :7895-7900
[8]   Involvement of 5-hydroxytryptamine1A receptors in Δ9-tetrahydrocannabinol-induced catalepsy-like immobilization in mice [J].
Egashira, Nobuaki ;
Matsuda, Tomomi ;
Koushi, Emi ;
Mishima, Kenichi ;
Iwasaki, Katsunori ;
Shoyama, Yukihiro ;
Fujiwara, Michihiro .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 550 (1-3) :117-122
[9]   MODIFICATION OF DELTA-9-THC ACTIONS BY CANNABINOL AND CANNABIDIOL IN RAT [J].
FERNANDES, M ;
SCHABAREK, A ;
COPER, H ;
HILL, R .
PSYCHOPHARMACOLOGIA, 1974, 38 (04) :329-338
[10]   New perspectives in the studies on endocannabinoid and cannabis:: Abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application [J].
Fujiwara, M ;
Egashira, N .
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 96 (04) :362-366